Revance Therapeutics Inc. (RVNC) had a rough trading day for Monday March 08 as
tumbled 8.6%, or a loss of $-2.26 per share, to close at $24.03. After opening the day at $26.61, shares of Revance Therapeutics Inc. traded as high as $26.97 and as
low as $24.00. Volume was 605,934 shares over 6,155 trades, against an average daily volume of n/a shares and a total float of 69.85 million.
As a result of the decline, Revance Therapeutics Inc. now has a market cap of $1.68 billion. In the last
year, shares of Revance Therapeutics Inc. have traded between a range of $34.62 and $11.78, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
For a complete fundamental analysis of Revance Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for
Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in research and development of aesthetic and therapeutic products.
Revance Therapeutics Inc. is based out of Nashville, TN and has some 470 employees. Its CEO is Mark J. Foley.
Revance Therapeutics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an
industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an
objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives
a broad, unbiased look at the small-cap market as a whole.
To get more information on Revance Therapeutics Inc. and to follow the company’s latest updates, you can visit the company’s profile page here:
RVNC’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s
Newsdesk. Also, don’t forget to sign-up for our daily
email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer